JAK3 and B-cell non-Hodgkin lymphoma: For instance, Bruton’s tyrosine kinase (BTK) and Janus kinase 3 (JAK3) are two validated and therapeutically amenable targets to effectively treat B-cell lymphomas and can be used to develop a dual-target inhibitor [8].